This panel seeks to get to the bottom of the IFR and what it means for the hemp CBD industry currently and in the future. We may also touch on the intersection of USDA and FDA authority to regulate hemp-derived CBD products.
As hemp policy continues to evolve, ensure you are staying at the forefront of regulatory developments to provide your clients with the best counsel for the 2021 production season.
With a new Administration and Congress, changes in personnel at FDA and new safety data being published, is 2021 the year when CBD will come out from under the FDA shadows to be legally marketed in all 50state?
Since the 2018 Farm Bill legalized hemp, there are now two distinct commercial industries: pharmaceuticals / wellness and industrial. In the pharmaceutical and consumer wellness areas, there is an explosion of innovation and new products. In the industrial market, there is increasing interest in light of sustainability and carbon capture considerations.
Our distinguished panel of judges will hear argument from both sides—petitioners and the government—and make a decision regarding the legality of marijuana’s continued classification as a Schedule I substance. Come see the exciting hearing unfold!
In this session the panelists will discuss international hemp-derived products trade. More specifically, the panelists will offer an overview of what transatlantic trade of hemp-derived products (food products, cosmetic products, vaping products…) for consumer use looks like with a particular focus on import and export of these products from the US market to the EU and/or the UK market(s) and from the EU and/or the UK to the USA.